Long-term safety of romosozumab for osteogenesis imperfecta in children
Treatments studied
Part of Bones, joints & muscles, Genetic & congenital, Skin clinical trials.
This study follows children who previously received romosozumab in an earlier trial to check their long-term safety. It helps understand if the treatment's benefits last safely over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been in the earlier romosozumab trial and received the drug
- You must have completed that trial through the 15-month visit
- You cannot be in any other experimental drug or device trial right now, or have been in one within the last 2 years (except for the earlier romosozumab trial)
- You and your family must be able to attend all scheduled visits and follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cell-based treatment to improve bone strength in children with the most severe type of osteogenesis imperfecta (brittle bone disease). If you qualify, it may help slow bone weakening and support growth.
This study follows people with osteogenesis imperfecta (OI) to better understand how it affects bones and related issues over time. It may help doctors learn which features and genetic changes predict problems, and guide future care.
This study looks at heart structure and function in children and adults with osteogenesis imperfecta (OI), a condition that affects bones. Researchers want to understand how OI may impact the heart.
This trial tests an adapted physical activity program to help children and teenagers rebuild strength and improve effort/fitness. It may be helpful if you want a tailored exercise approach that is safe for osteogenesis imperfecta.
This trial is testing a medicine called romosozumab to treat postmenopausal women with severe osteoporosis and a recent fracture. It aims to find the best way to use this drug to strengthen bones and prevent more fractures.
This study looks at what changes in the body after starting romosozumab (an osteoporosis treatment) in postmenopausal women at higher risk for fractures. Researchers want to understand the treatment’s “mechanism,” which may help improve future osteoporosis care.
Hear when a new Osteogenesis Imperfecta trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.